Table 1.
Patient characteristics.
| Characteristics | Total Cohort (n = 36) |
Patients with a cCR (n = 15) |
Patients with Residual Tumor (n = 21) |
|||
|---|---|---|---|---|---|---|
| Median age (years) (range) | 66 | 38–86 | 67 | 54–86 | 66 | 38–79 |
| Sex (n, %) | ||||||
| Male | 21 | 58 | 9 | 60 | 12 | 57 |
| Female | 15 | 42 | 6 | 40 | 9 | 43 |
| Clinical tumor stage (n, %) | ||||||
| cT2 | 9 | 25 | 6 | 40 | 3 | 14 |
| cT3 | 26 | 72 | 8 | 53 | 18 | 86 |
| cT4 | 1 | 3 | 1 | 7 | 0 | 0 |
| Clinical nodal stage (n, %) | ||||||
| cN0 | 20 | 56 | 9 | 60 | 11 | 52 |
| cN1 | 12 | 33 | 6 | 40 | 6 | 29 |
| cN2 | 4 | 11 | 0 | 0 | 4 | 19 |
| Neoadjuvant radiotherapy (n, %) | ||||||
| Short-course radiotherapy | 7 | 19 | 7 | 47 | 0 | 0 |
| (Chemo)radiotherapy | 29 | 81 | 8 | 53 | 21 | 100 |
| Clinical nodal stage prior to CXB (n, %) | ||||||
| ycN0 | 34 | 94 | 14 | 93 | 20 | 95 |
| ycN1 | 2 | 6 | 1 | 7 | 1 | 4 |
| Clinical distant metastasis prior to CXB (n, %) | ||||||
| ycM0 | 33 | 92 | 14 | 93 | 19 | 90 |
| ycM1 | 3 | 8 | 1 | 7 | 2 | 10 |
| Median size tumor prior to CXB on MRI (cm) (range) | 2.2 | 0.8–4.2 | 1.9 | 1.0–3.0 | 2.0 | 0.8–4.2 |
| Median size tumor prior to CXB on endoscopy (cm) (range) | 2.0 | 1.0–4.0 | 2.0 | 1.0–2.5 | 2.0 | 1.0–4.0 |
| Median interval neoadjuvant radiotherapy and CXB (months) (range) | 3 | 2–38 | 2 | 2–21 | 4 | 2–38 |
| Patients treated with TME surgery following CXB (n, %) | 19 | 53 | 1 | 7 | 18 | 86 |
Abbreviations: CXB = contact X-ray brachytherapy, cCR = clinical complete response.